ArticleJournal of thoracic disease2018
Prognostic value of immunohistochemical factors in esophageal small cell carcinoma (ESCC): analysis of clinicopathologic features of 73 patients.
Article in Journal of thoracic disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 11 citations in OpenAlex.
- Extensive-stage small cell esophageal carcinoma: a retrospective analysis of treatment modalities.BMC cancer · 2026Article
- The role of radiotherapy in small cell carcinoma of the esophagus: a retrospective study.Radiation oncology (London, England) · 2025Article
- NSE and ProGRP Are Promising Markers for Diagnosis, Efficacy Evaluation, Follow-Up Monitoring, and Prognosis of Small Cell Esophageal Carcinoma.Thoracic cancer · 2025Article
- CircRNA PDE3B regulates tumorigenicity via the miR-136-5p/MAP3K2 axis of esophageal squamous cell carcinoma.Histology and histopathology · 2023Article
- Graphene-Based Electrochemical Sensor for Detection of Hepatocellular Carcinoma Markers.Frontiers in chemistry · 2022Review
- Diagnostic Immunostaining and Tumor Markers Predict the Prognosis of Esophageal Neuroendocrine Cell Carcinoma Patients.Annals of surgical oncology · 2021Article
- Review
- Primary small cell carcinoma of the esophagus: progression in the last decade.Annals of translational medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEsophageal small cell carcinoma (ESCC) is an aggressive disease with poor prognosis. This study sought to describe immunohistochemical (IHC) and clinicopathological features of patients with ESCC, and to clarify how the utilization of different marker combination affects prognostic outcome.
methodsThe paraffin-embedded ESCC samples of 73 patients were immunohistochemically analyzed of neuron specific enolase (NSE), chromogranin A (CgA), synaptophysin (Syn) and thyroid transcriptional factor-1 (TTF-1). The positivity of these factors and their correlation with clinical characteristics was described. The relation between positive expression of them and survival was also analyzed.
resultsImmunological reactivity of the samples was Syn 68.5%, TTF-1 49.3%, NSE 90.4%, CgA 43.8%. There were 18 patients with 4 biomarkers positive (24.7%), 24 patients with 3 biomarkers positive (32.9%), 14 patients with 2 biomarkers positive (19.2%) and 12 patients with only 1 biomarker positive (16.4%). Five cases (6.8%) were all negative. The 2- and 3-year survivals were 24.8% and 19.9%, respectively. The mOS of patients without expression of four factors was significant worse than those with at least one factor of positive expression (6.1
conclusionsPatients with ESCC have a poor prognosis. The positive labeling of Syn, CgA, NSE and TTF-1 implicated their favourable prognostic value trend. These factors or their combination might serve as useful markers in prognostic evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.